Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 260 | 2025 | 21053 | 11.010 |
Why?
|
Neoadjuvant Therapy | 92 | 2024 | 2895 | 6.910 |
Why?
|
Sentinel Lymph Node Biopsy | 60 | 2025 | 727 | 6.820 |
Why?
|
Cancer Vaccines | 43 | 2023 | 1044 | 6.760 |
Why?
|
Receptor, erbB-2 | 80 | 2025 | 2592 | 6.760 |
Why?
|
Mastectomy, Segmental | 26 | 2024 | 964 | 4.130 |
Why?
|
Lymph Node Excision | 49 | 2024 | 1259 | 3.880 |
Why?
|
Axilla | 54 | 2024 | 615 | 3.870 |
Why?
|
Neoplasm Staging | 96 | 2024 | 11201 | 3.650 |
Why?
|
Carcinoma, Ductal, Breast | 32 | 2020 | 1082 | 3.220 |
Why?
|
Neoplasm Recurrence, Local | 62 | 2024 | 9368 | 3.180 |
Why?
|
Lymph Nodes | 39 | 2023 | 3451 | 3.070 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 18 | 2024 | 920 | 2.930 |
Why?
|
Receptors, Estrogen | 40 | 2025 | 2240 | 2.750 |
Why?
|
Carcinoma, Lobular | 18 | 2020 | 470 | 2.610 |
Why?
|
Mastectomy | 36 | 2024 | 1847 | 2.600 |
Why?
|
Vaccines, Subunit | 15 | 2023 | 158 | 2.350 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 57 | 2024 | 11865 | 2.060 |
Why?
|
Immunotherapy | 33 | 2024 | 4752 | 2.060 |
Why?
|
Peptide Fragments | 24 | 2023 | 5125 | 2.010 |
Why?
|
Lymphatic Metastasis | 53 | 2023 | 2882 | 2.010 |
Why?
|
Neoplasm, Residual | 12 | 2024 | 1009 | 1.860 |
Why?
|
Chemotherapy, Adjuvant | 49 | 2024 | 3537 | 1.740 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 13 | 2024 | 1105 | 1.630 |
Why?
|
Receptors, Progesterone | 24 | 2025 | 1152 | 1.510 |
Why?
|
Prognosis | 77 | 2025 | 29899 | 1.470 |
Why?
|
Female | 294 | 2025 | 395961 | 1.370 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 13 | 2023 | 890 | 1.270 |
Why?
|
HLA-A2 Antigen | 10 | 2023 | 207 | 1.230 |
Why?
|
T-Lymphocytes, Cytotoxic | 15 | 2020 | 1801 | 1.190 |
Why?
|
Leukocyte Elastase | 5 | 2017 | 113 | 1.190 |
Why?
|
Paclitaxel | 13 | 2024 | 1728 | 1.180 |
Why?
|
Humans | 346 | 2025 | 765734 | 1.120 |
Why?
|
Disease-Free Survival | 25 | 2024 | 6832 | 0.900 |
Why?
|
Antigens, Neoplasm | 11 | 2023 | 1998 | 0.880 |
Why?
|
SEER Program | 6 | 2024 | 1444 | 0.870 |
Why?
|
Inflammatory Breast Neoplasms | 3 | 2024 | 150 | 0.870 |
Why?
|
Aged | 134 | 2024 | 171050 | 0.860 |
Why?
|
Survival Rate | 36 | 2025 | 12787 | 0.820 |
Why?
|
CD8-Positive T-Lymphocytes | 11 | 2020 | 4642 | 0.810 |
Why?
|
Neoplastic Cells, Circulating | 5 | 2019 | 949 | 0.800 |
Why?
|
Middle Aged | 152 | 2025 | 222903 | 0.780 |
Why?
|
Biological Factors | 2 | 2020 | 155 | 0.710 |
Why?
|
Lymphedema | 6 | 2024 | 525 | 0.710 |
Why?
|
Tumor Microenvironment | 15 | 2024 | 3948 | 0.690 |
Why?
|
Adult | 135 | 2024 | 222974 | 0.680 |
Why?
|
Aged, 80 and over | 66 | 2024 | 59459 | 0.660 |
Why?
|
Cytotoxicity, Immunologic | 5 | 2020 | 1347 | 0.660 |
Why?
|
Follow-Up Studies | 53 | 2024 | 39180 | 0.620 |
Why?
|
Parathyroidectomy | 4 | 2007 | 244 | 0.610 |
Why?
|
Tamoxifen | 4 | 2024 | 963 | 0.610 |
Why?
|
Folate Receptors, GPI-Anchored | 1 | 2018 | 23 | 0.610 |
Why?
|
Neoplasm Invasiveness | 17 | 2020 | 3595 | 0.600 |
Why?
|
Antineoplastic Agents | 17 | 2024 | 13639 | 0.590 |
Why?
|
Combined Modality Therapy | 22 | 2024 | 8528 | 0.590 |
Why?
|
Albumins | 1 | 2020 | 577 | 0.580 |
Why?
|
Thyroidectomy | 6 | 2008 | 911 | 0.580 |
Why?
|
Breast | 12 | 2024 | 1946 | 0.570 |
Why?
|
Nomograms | 4 | 2016 | 235 | 0.560 |
Why?
|
Continuity of Patient Care | 1 | 2024 | 1078 | 0.540 |
Why?
|
Prospective Studies | 50 | 2024 | 54795 | 0.530 |
Why?
|
Estrogen Receptor alpha | 2 | 2019 | 579 | 0.510 |
Why?
|
Testicular Neoplasms | 1 | 2021 | 786 | 0.500 |
Why?
|
Antigen Presentation | 6 | 2023 | 1250 | 0.490 |
Why?
|
Hyperparathyroidism | 4 | 2007 | 337 | 0.490 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2020 | 1533 | 0.480 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2019 | 825 | 0.480 |
Why?
|
Dendritic Cells | 7 | 2019 | 2746 | 0.480 |
Why?
|
Ferrosoferric Oxide | 1 | 2016 | 349 | 0.460 |
Why?
|
Vaccination | 9 | 2018 | 3427 | 0.460 |
Why?
|
Radiotherapy | 2 | 2020 | 1494 | 0.450 |
Why?
|
Neoplasms | 13 | 2022 | 22345 | 0.440 |
Why?
|
Dextrans | 1 | 2016 | 570 | 0.440 |
Why?
|
Ovarian Neoplasms | 4 | 2019 | 4900 | 0.430 |
Why?
|
Observer Variation | 3 | 2024 | 2611 | 0.420 |
Why?
|
Treatment Outcome | 49 | 2024 | 65180 | 0.410 |
Why?
|
Antibodies, Monoclonal | 13 | 2024 | 9245 | 0.410 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2022 | 5388 | 0.410 |
Why?
|
Hypocalcemia | 3 | 2004 | 205 | 0.410 |
Why?
|
Patient Preference | 1 | 2020 | 952 | 0.410 |
Why?
|
Pathology, Clinical | 1 | 2016 | 374 | 0.390 |
Why?
|
Gene Expression Profiling | 7 | 2024 | 9522 | 0.390 |
Why?
|
Adrenal Gland Neoplasms | 2 | 2008 | 728 | 0.390 |
Why?
|
Adjuvants, Immunologic | 6 | 2016 | 995 | 0.390 |
Why?
|
Mast Cells | 1 | 2019 | 1411 | 0.380 |
Why?
|
Health Plan Implementation | 1 | 2014 | 338 | 0.360 |
Why?
|
Cell Line, Tumor | 20 | 2023 | 17062 | 0.360 |
Why?
|
Retrospective Studies | 46 | 2024 | 81457 | 0.350 |
Why?
|
Adenocarcinoma | 5 | 2011 | 6356 | 0.350 |
Why?
|
Biology | 2 | 2024 | 293 | 0.350 |
Why?
|
Histocompatibility Antigens Class II | 2 | 2019 | 1440 | 0.350 |
Why?
|
GPI-Linked Proteins | 1 | 2012 | 472 | 0.350 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2016 | 1364 | 0.340 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2011 | 639 | 0.340 |
Why?
|
Thyroid Neoplasms | 5 | 2022 | 2350 | 0.340 |
Why?
|
Peptides | 6 | 2024 | 4331 | 0.340 |
Why?
|
Ketones | 2 | 2021 | 183 | 0.340 |
Why?
|
Furans | 2 | 2021 | 198 | 0.330 |
Why?
|
Cyclin E | 1 | 2010 | 155 | 0.330 |
Why?
|
Immunotherapy, Adoptive | 2 | 2020 | 1511 | 0.330 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2657 | 0.330 |
Why?
|
Taxoids | 6 | 2023 | 665 | 0.320 |
Why?
|
Genes, erbB-2 | 2 | 2010 | 160 | 0.320 |
Why?
|
Mastectomy, Simple | 3 | 2017 | 23 | 0.310 |
Why?
|
Young Adult | 37 | 2024 | 59852 | 0.300 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2009 | 318 | 0.300 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2024 | 8603 | 0.300 |
Why?
|
Decision Making | 7 | 2024 | 3964 | 0.300 |
Why?
|
Cross-Priming | 4 | 2018 | 75 | 0.300 |
Why?
|
Biopsy, Needle | 5 | 2018 | 1617 | 0.290 |
Why?
|
Lung Neoplasms | 5 | 2022 | 13448 | 0.290 |
Why?
|
Cathepsin G | 3 | 2022 | 41 | 0.290 |
Why?
|
Rosaniline Dyes | 3 | 2019 | 51 | 0.290 |
Why?
|
Carboplatin | 4 | 2024 | 789 | 0.290 |
Why?
|
Drug Discovery | 1 | 2015 | 1063 | 0.290 |
Why?
|
False Negative Reactions | 6 | 2017 | 568 | 0.280 |
Why?
|
Clinical Trials as Topic | 12 | 2024 | 8038 | 0.280 |
Why?
|
Single-Blind Method | 4 | 2020 | 1589 | 0.280 |
Why?
|
Parathyroid Neoplasms | 2 | 2007 | 244 | 0.280 |
Why?
|
Life Expectancy | 2 | 2024 | 1248 | 0.280 |
Why?
|
Carcinoma, Islet Cell | 1 | 2006 | 21 | 0.270 |
Why?
|
Cyclophosphamide | 5 | 2024 | 2227 | 0.270 |
Why?
|
Neoplasm Metastasis | 10 | 2024 | 4885 | 0.270 |
Why?
|
Radiotherapy, Adjuvant | 8 | 2024 | 1775 | 0.260 |
Why?
|
Survival Analysis | 14 | 2021 | 10069 | 0.260 |
Why?
|
Societies, Medical | 6 | 2021 | 3955 | 0.260 |
Why?
|
Magnetite Nanoparticles | 2 | 2019 | 309 | 0.260 |
Why?
|
HLA-A3 Antigen | 4 | 2014 | 34 | 0.250 |
Why?
|
Tumor Escape | 2 | 2020 | 371 | 0.250 |
Why?
|
Sternum | 2 | 2019 | 176 | 0.250 |
Why?
|
United States | 23 | 2024 | 72898 | 0.250 |
Why?
|
Kaplan-Meier Estimate | 10 | 2024 | 6499 | 0.250 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 2005 | 318 | 0.240 |
Why?
|
Lithiasis | 1 | 2005 | 19 | 0.240 |
Why?
|
Electronic Health Records | 1 | 2022 | 4862 | 0.240 |
Why?
|
Pheochromocytoma | 1 | 2007 | 323 | 0.240 |
Why?
|
Cecal Diseases | 1 | 2005 | 49 | 0.240 |
Why?
|
Hyperparathyroidism, Primary | 1 | 2007 | 163 | 0.240 |
Why?
|
Rectus Abdominis | 1 | 2005 | 101 | 0.230 |
Why?
|
Hematologic Neoplasms | 1 | 2016 | 1926 | 0.230 |
Why?
|
Pancreatic Neoplasms | 4 | 2020 | 5442 | 0.230 |
Why?
|
Biliary Fistula | 1 | 2004 | 38 | 0.230 |
Why?
|
Medical Oncology | 4 | 2019 | 2339 | 0.230 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2024 | 99 | 0.230 |
Why?
|
Insulinoma | 1 | 2004 | 121 | 0.220 |
Why?
|
Ultrasonography | 8 | 2022 | 5986 | 0.220 |
Why?
|
T-Lymphocytes | 5 | 2022 | 10262 | 0.220 |
Why?
|
Carcinoma, Papillary | 2 | 2007 | 782 | 0.220 |
Why?
|
Stomach Ulcer | 1 | 2004 | 118 | 0.220 |
Why?
|
Appendix | 1 | 2005 | 109 | 0.220 |
Why?
|
Thyroid Nodule | 2 | 2002 | 765 | 0.220 |
Why?
|
Epitopes | 6 | 2012 | 2523 | 0.220 |
Why?
|
Intestinal Fistula | 1 | 2004 | 146 | 0.210 |
Why?
|
Inflammation Mediators | 1 | 2012 | 1885 | 0.210 |
Why?
|
Patient Selection | 5 | 2023 | 4254 | 0.210 |
Why?
|
Biopsy, Fine-Needle | 2 | 2018 | 1129 | 0.210 |
Why?
|
Gallbladder Diseases | 1 | 2004 | 139 | 0.210 |
Why?
|
Abdominal Pain | 3 | 2005 | 1069 | 0.210 |
Why?
|
Hematoma | 2 | 2005 | 766 | 0.210 |
Why?
|
Lymphatic Vessels | 2 | 2022 | 355 | 0.210 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2005 | 345 | 0.210 |
Why?
|
Hyperparathyroidism, Secondary | 1 | 2004 | 123 | 0.210 |
Why?
|
Biological Products | 2 | 2022 | 942 | 0.210 |
Why?
|
Postmenopause | 5 | 2024 | 2516 | 0.210 |
Why?
|
Doxorubicin | 3 | 2024 | 2229 | 0.210 |
Why?
|
Adaptive Immunity | 2 | 2019 | 734 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3101 | 0.200 |
Why?
|
Colonic Diseases | 1 | 2004 | 204 | 0.200 |
Why?
|
Models, Statistical | 1 | 2017 | 5088 | 0.200 |
Why?
|
Enoxaparin | 1 | 2005 | 390 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3224 | 0.200 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2024 | 10385 | 0.200 |
Why?
|
Myeloblastin | 2 | 2012 | 99 | 0.200 |
Why?
|
Genetic Testing | 3 | 2021 | 3592 | 0.200 |
Why?
|
Practice Guidelines as Topic | 6 | 2017 | 7424 | 0.190 |
Why?
|
Tumor Cells, Cultured | 5 | 2017 | 6109 | 0.190 |
Why?
|
Melanoma | 4 | 2022 | 5690 | 0.190 |
Why?
|
Gene Expression Regulation | 2 | 2019 | 11888 | 0.190 |
Why?
|
Predictive Value of Tests | 9 | 2021 | 15390 | 0.190 |
Why?
|
Technetium | 2 | 2019 | 326 | 0.190 |
Why?
|
Pyrazoles | 2 | 2024 | 2031 | 0.190 |
Why?
|
Quality Control | 1 | 2024 | 835 | 0.190 |
Why?
|
Tumor Burden | 6 | 2019 | 1884 | 0.190 |
Why?
|
PTEN Phosphohydrolase | 2 | 2020 | 1118 | 0.180 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2019 | 4405 | 0.180 |
Why?
|
SOXC Transcription Factors | 1 | 2020 | 42 | 0.180 |
Why?
|
Adenoma | 3 | 2007 | 2152 | 0.180 |
Why?
|
Accreditation | 1 | 2024 | 477 | 0.180 |
Why?
|
Carcinoma in Situ | 2 | 2020 | 776 | 0.180 |
Why?
|
Premenopause | 3 | 2021 | 1038 | 0.180 |
Why?
|
Immune Tolerance | 1 | 2010 | 2324 | 0.180 |
Why?
|
Phthalazines | 2 | 2022 | 397 | 0.180 |
Why?
|
Cohort Studies | 14 | 2024 | 41631 | 0.180 |
Why?
|
Melanoma, Experimental | 2 | 2021 | 556 | 0.170 |
Why?
|
Radiopharmaceuticals | 4 | 2023 | 2699 | 0.170 |
Why?
|
Disease Management | 3 | 2019 | 2534 | 0.170 |
Why?
|
Databases, Factual | 5 | 2019 | 8062 | 0.170 |
Why?
|
Mammaplasty | 3 | 2016 | 1264 | 0.170 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2024 | 5336 | 0.170 |
Why?
|
Thyrotoxicosis | 1 | 2001 | 85 | 0.170 |
Why?
|
Hypersensitivity, Delayed | 3 | 2018 | 490 | 0.170 |
Why?
|
Camptothecin | 1 | 2023 | 600 | 0.170 |
Why?
|
Immunization, Secondary | 2 | 2014 | 373 | 0.170 |
Why?
|
Lidocaine | 1 | 2023 | 550 | 0.170 |
Why?
|
Xanthones | 1 | 2019 | 23 | 0.160 |
Why?
|
Immunohistochemistry | 4 | 2024 | 11007 | 0.160 |
Why?
|
Parathyroid Hormone | 2 | 2005 | 1789 | 0.160 |
Why?
|
Glycosylation | 2 | 2019 | 1099 | 0.160 |
Why?
|
Comprehension | 1 | 2024 | 638 | 0.160 |
Why?
|
Medicare | 4 | 2024 | 6821 | 0.150 |
Why?
|
Health Literacy | 1 | 2024 | 465 | 0.150 |
Why?
|
Animals | 26 | 2024 | 168731 | 0.150 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2021 | 498 | 0.150 |
Why?
|
Proportional Hazards Models | 11 | 2018 | 12509 | 0.150 |
Why?
|
Nitriles | 1 | 2024 | 982 | 0.150 |
Why?
|
Risk | 6 | 2021 | 9592 | 0.150 |
Why?
|
Hormones | 1 | 2022 | 863 | 0.150 |
Why?
|
Immunophenotyping | 2 | 2024 | 1865 | 0.150 |
Why?
|
Megakaryocytes | 1 | 2022 | 557 | 0.150 |
Why?
|
Transendothelial and Transepithelial Migration | 1 | 2019 | 100 | 0.150 |
Why?
|
Receptors, Androgen | 1 | 2024 | 1087 | 0.150 |
Why?
|
Pyrimidinones | 1 | 2020 | 384 | 0.150 |
Why?
|
General Surgery | 3 | 2015 | 1722 | 0.150 |
Why?
|
Multivariate Analysis | 6 | 2018 | 12056 | 0.150 |
Why?
|
Carcinoma | 2 | 2010 | 2309 | 0.150 |
Why?
|
Tracheostomy | 1 | 2002 | 429 | 0.150 |
Why?
|
Registries | 5 | 2022 | 8293 | 0.150 |
Why?
|
Mutation | 11 | 2024 | 30184 | 0.140 |
Why?
|
Frail Elderly | 1 | 2023 | 785 | 0.140 |
Why?
|
Mucin-1 | 2 | 2012 | 531 | 0.140 |
Why?
|
Ferric Compounds | 1 | 2019 | 368 | 0.140 |
Why?
|
Interferons | 2 | 2019 | 714 | 0.140 |
Why?
|
Vertebral Artery | 1 | 1998 | 185 | 0.140 |
Why?
|
Neuropilin-1 | 1 | 2017 | 90 | 0.140 |
Why?
|
Mice | 16 | 2022 | 81792 | 0.130 |
Why?
|
Vaccines, Attenuated | 1 | 2018 | 312 | 0.130 |
Why?
|
Anthracyclines | 3 | 2023 | 284 | 0.130 |
Why?
|
Preoperative Care | 2 | 2024 | 2266 | 0.130 |
Why?
|
Immune System | 1 | 2022 | 799 | 0.130 |
Why?
|
Skin Neoplasms | 4 | 2012 | 5824 | 0.130 |
Why?
|
Quality of Life | 3 | 2024 | 13462 | 0.130 |
Why?
|
Nanomedicine | 1 | 2019 | 286 | 0.130 |
Why?
|
Aromatase Inhibitors | 1 | 2020 | 518 | 0.130 |
Why?
|
Integrins | 1 | 2020 | 839 | 0.130 |
Why?
|
Mediastinal Neoplasms | 1 | 2019 | 403 | 0.130 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2019 | 657 | 0.130 |
Why?
|
ROC Curve | 3 | 2019 | 3618 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2023 | 979 | 0.130 |
Why?
|
Benchmarking | 1 | 2022 | 1053 | 0.130 |
Why?
|
Artifacts | 1 | 2024 | 1893 | 0.130 |
Why?
|
Parathyroid Glands | 2 | 2008 | 521 | 0.130 |
Why?
|
Signal Transduction | 9 | 2024 | 23589 | 0.130 |
Why?
|
Chromium | 2 | 2006 | 132 | 0.130 |
Why?
|
Tissue Distribution | 2 | 2019 | 2266 | 0.120 |
Why?
|
Double-Blind Method | 2 | 2020 | 12433 | 0.120 |
Why?
|
Incidence | 9 | 2018 | 21478 | 0.120 |
Why?
|
Glypicans | 1 | 2015 | 33 | 0.120 |
Why?
|
International Agencies | 1 | 2016 | 239 | 0.120 |
Why?
|
Feasibility Studies | 6 | 2018 | 5302 | 0.120 |
Why?
|
Hypoparathyroidism | 2 | 2008 | 136 | 0.120 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2024 | 8926 | 0.120 |
Why?
|
NF-kappa B | 1 | 2023 | 2486 | 0.120 |
Why?
|
Multigene Family | 1 | 2018 | 1081 | 0.120 |
Why?
|
Antigens, CD | 1 | 2005 | 4020 | 0.120 |
Why?
|
Mice, Inbred BALB C | 3 | 2021 | 6219 | 0.120 |
Why?
|
Monocytes | 1 | 2024 | 2594 | 0.120 |
Why?
|
Cisplatin | 1 | 2020 | 1657 | 0.120 |
Why?
|
Bone Neoplasms | 3 | 2019 | 2564 | 0.110 |
Why?
|
Intraoperative Care | 1 | 2018 | 760 | 0.110 |
Why?
|
Education, Medical, Continuing | 2 | 2015 | 830 | 0.110 |
Why?
|
Patient Education as Topic | 1 | 2024 | 2335 | 0.110 |
Why?
|
Clinical Competence | 2 | 2015 | 4862 | 0.110 |
Why?
|
Risk Factors | 14 | 2022 | 74831 | 0.110 |
Why?
|
Radiation Oncology | 1 | 2020 | 569 | 0.110 |
Why?
|
Bone Marrow | 1 | 2024 | 2918 | 0.110 |
Why?
|
Surgical Instruments | 3 | 2022 | 379 | 0.110 |
Why?
|
California | 1 | 2018 | 1434 | 0.110 |
Why?
|
Enteral Nutrition | 1 | 1999 | 803 | 0.110 |
Why?
|
Respiratory Insufficiency | 1 | 2002 | 1240 | 0.110 |
Why?
|
Data Collection | 1 | 2022 | 3318 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 5 | 2017 | 20667 | 0.110 |
Why?
|
Point-of-Care Systems | 1 | 2002 | 1217 | 0.110 |
Why?
|
Cerebral Infarction | 1 | 1998 | 970 | 0.100 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2538 | 0.100 |
Why?
|
Kidney Diseases | 1 | 2004 | 2097 | 0.100 |
Why?
|
Extremities | 1 | 2018 | 869 | 0.100 |
Why?
|
Adolescent | 12 | 2024 | 88781 | 0.100 |
Why?
|
Hepatitis C | 1 | 2023 | 1597 | 0.100 |
Why?
|
Survival | 1 | 2013 | 160 | 0.100 |
Why?
|
Brain Stem | 1 | 1998 | 854 | 0.100 |
Why?
|
Reproducibility of Results | 4 | 2018 | 20120 | 0.100 |
Why?
|
Immunoenzyme Techniques | 1 | 2015 | 1696 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2024 | 2878 | 0.100 |
Why?
|
Drug Monitoring | 1 | 2018 | 961 | 0.100 |
Why?
|
Social Class | 1 | 2021 | 2007 | 0.100 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2016 | 584 | 0.100 |
Why?
|
Cell Proliferation | 3 | 2017 | 10428 | 0.100 |
Why?
|
Ki-67 Antigen | 2 | 2023 | 627 | 0.100 |
Why?
|
Nanotechnology | 1 | 2017 | 703 | 0.100 |
Why?
|
Wounds, Gunshot | 1 | 1998 | 585 | 0.100 |
Why?
|
Laparoscopy | 1 | 2003 | 2039 | 0.100 |
Why?
|
Endoscopy | 1 | 2001 | 1849 | 0.100 |
Why?
|
Thoracic Wall | 1 | 2013 | 197 | 0.100 |
Why?
|
Pyrimidines | 1 | 2024 | 3044 | 0.090 |
Why?
|
Certification | 1 | 2015 | 419 | 0.090 |
Why?
|
Thoracic Neoplasms | 1 | 2013 | 267 | 0.090 |
Why?
|
Glycomics | 1 | 2012 | 118 | 0.090 |
Why?
|
Intensive Care Units | 2 | 2002 | 3800 | 0.090 |
Why?
|
Academic Medical Centers | 2 | 2023 | 2779 | 0.090 |
Why?
|
Male | 21 | 2022 | 363585 | 0.090 |
Why?
|
Age Factors | 8 | 2019 | 18375 | 0.090 |
Why?
|
Glycopeptides | 1 | 2012 | 224 | 0.090 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2020 | 3605 | 0.090 |
Why?
|
Folate Receptor 1 | 1 | 2011 | 41 | 0.090 |
Why?
|
Drug Design | 1 | 2016 | 1042 | 0.090 |
Why?
|
Lymphocyte Activation | 2 | 2019 | 5501 | 0.090 |
Why?
|
Interferon-gamma | 1 | 2019 | 3159 | 0.090 |
Why?
|
Arm | 2 | 2024 | 588 | 0.090 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2013 | 258 | 0.090 |
Why?
|
Metformin | 1 | 2018 | 904 | 0.090 |
Why?
|
Postoperative Period | 3 | 2016 | 1816 | 0.090 |
Why?
|
Exosomes | 1 | 2015 | 421 | 0.090 |
Why?
|
Cerebellum | 1 | 1998 | 1519 | 0.090 |
Why?
|
Appendectomy | 2 | 2005 | 444 | 0.090 |
Why?
|
Software | 1 | 2024 | 4459 | 0.090 |
Why?
|
Dimerization | 1 | 2012 | 880 | 0.090 |
Why?
|
Postoperative Complications | 5 | 2016 | 15749 | 0.090 |
Why?
|
DNA Primers | 2 | 2012 | 2823 | 0.090 |
Why?
|
Disease Progression | 6 | 2011 | 13614 | 0.090 |
Why?
|
Patient-Centered Care | 1 | 2020 | 1458 | 0.080 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2011 | 299 | 0.080 |
Why?
|
Germ-Line Mutation | 3 | 2022 | 1883 | 0.080 |
Why?
|
Medical Records | 3 | 2013 | 1409 | 0.080 |
Why?
|
Algorithms | 2 | 2007 | 14061 | 0.080 |
Why?
|
Risk Assessment | 9 | 2023 | 24279 | 0.080 |
Why?
|
Specialties, Surgical | 1 | 2014 | 391 | 0.080 |
Why?
|
Poverty | 1 | 2021 | 2714 | 0.080 |
Why?
|
Anticoagulants | 1 | 2005 | 4862 | 0.080 |
Why?
|
Immunologic Memory | 1 | 2016 | 1375 | 0.080 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 1600 | 0.080 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2013 | 616 | 0.080 |
Why?
|
Hyperplasia | 2 | 2005 | 1144 | 0.080 |
Why?
|
Time Factors | 7 | 2024 | 40066 | 0.080 |
Why?
|
Mice, Transgenic | 2 | 2021 | 9548 | 0.080 |
Why?
|
G1 Phase | 1 | 2010 | 403 | 0.080 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2016 | 3640 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 3 | 2021 | 18061 | 0.080 |
Why?
|
Likelihood Functions | 1 | 2012 | 993 | 0.080 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 2008 | 185 | 0.080 |
Why?
|
Mice, Nude | 2 | 2015 | 3614 | 0.070 |
Why?
|
Hepatectomy | 1 | 2012 | 589 | 0.070 |
Why?
|
Biomedical Research | 1 | 2023 | 3458 | 0.070 |
Why?
|
Molecular Weight | 1 | 2010 | 2163 | 0.070 |
Why?
|
Recurrence | 4 | 2012 | 8498 | 0.070 |
Why?
|
Myeloid Cells | 2 | 2024 | 839 | 0.070 |
Why?
|
Macrophages | 2 | 2020 | 5772 | 0.070 |
Why?
|
Palliative Care | 2 | 2020 | 3645 | 0.070 |
Why?
|
Sensitivity and Specificity | 4 | 2008 | 14637 | 0.070 |
Why?
|
Statistics, Nonparametric | 3 | 2016 | 2845 | 0.070 |
Why?
|
Socioeconomic Factors | 1 | 2021 | 7835 | 0.070 |
Why?
|
Lymphatic System | 1 | 2009 | 250 | 0.070 |
Why?
|
Appendicitis | 2 | 2005 | 679 | 0.070 |
Why?
|
Neck Dissection | 1 | 2008 | 200 | 0.070 |
Why?
|
Neoplasm Transplantation | 2 | 2021 | 2011 | 0.070 |
Why?
|
Calcium | 3 | 2007 | 5765 | 0.070 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2009 | 330 | 0.070 |
Why?
|
Immunity, Innate | 1 | 2019 | 3078 | 0.070 |
Why?
|
Surgery, Computer-Assisted | 1 | 2015 | 993 | 0.070 |
Why?
|
Meta-Analysis as Topic | 1 | 2012 | 1367 | 0.070 |
Why?
|
Databases, Genetic | 1 | 2014 | 1751 | 0.070 |
Why?
|
Antigen-Presenting Cells | 3 | 2018 | 962 | 0.070 |
Why?
|
Blood Cells | 1 | 2008 | 307 | 0.070 |
Why?
|
Coloring Agents | 3 | 2015 | 562 | 0.070 |
Why?
|
Drainage | 1 | 2012 | 1180 | 0.070 |
Why?
|
Estrogens | 2 | 2024 | 1529 | 0.070 |
Why?
|
Catecholamines | 1 | 2007 | 385 | 0.060 |
Why?
|
Apoptosis | 2 | 2023 | 9511 | 0.060 |
Why?
|
Adrenalectomy | 1 | 2008 | 344 | 0.060 |
Why?
|
Frozen Sections | 1 | 2006 | 152 | 0.060 |
Why?
|
Nanoparticles | 1 | 2017 | 1962 | 0.060 |
Why?
|
Lysosomal-Associated Membrane Protein 1 | 1 | 2005 | 25 | 0.060 |
Why?
|
Comorbidity | 1 | 2020 | 10567 | 0.060 |
Why?
|
Hypoglycemic Agents | 1 | 2018 | 3109 | 0.060 |
Why?
|
Pilot Projects | 4 | 2022 | 8732 | 0.060 |
Why?
|
Adaptation, Physiological | 1 | 2012 | 1308 | 0.060 |
Why?
|
Parathyroid Hormone-Related Protein | 1 | 2006 | 327 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2014 | 2454 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2017 | 3593 | 0.060 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 4563 | 0.060 |
Why?
|
Carcinoid Tumor | 1 | 2006 | 225 | 0.060 |
Why?
|
Cushing Syndrome | 1 | 2006 | 241 | 0.060 |
Why?
|
Genes, Retinoblastoma | 1 | 2005 | 125 | 0.060 |
Why?
|
Phenotype | 2 | 2021 | 16706 | 0.060 |
Why?
|
Adrenocorticotropic Hormone | 1 | 2006 | 618 | 0.060 |
Why?
|
Protein Binding | 3 | 2012 | 9299 | 0.060 |
Why?
|
Amino Acid Sequence | 3 | 2012 | 13403 | 0.060 |
Why?
|
Melena | 1 | 2004 | 32 | 0.060 |
Why?
|
Colloids | 2 | 2015 | 122 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2022 | 5891 | 0.060 |
Why?
|
Hematemesis | 1 | 2004 | 22 | 0.060 |
Why?
|
Biopsy | 3 | 2024 | 6754 | 0.060 |
Why?
|
Proteome | 1 | 2014 | 1897 | 0.060 |
Why?
|
Biological Transport | 2 | 2019 | 2080 | 0.060 |
Why?
|
Leukemia | 1 | 2012 | 1522 | 0.050 |
Why?
|
Fecal Impaction | 1 | 2003 | 32 | 0.050 |
Why?
|
Hematocrit | 1 | 2005 | 621 | 0.050 |
Why?
|
Molecular Sequence Data | 3 | 2012 | 17595 | 0.050 |
Why?
|
BRCA1 Protein | 2 | 2020 | 1154 | 0.050 |
Why?
|
Hernia | 1 | 2003 | 67 | 0.050 |
Why?
|
Cognition Disorders | 2 | 2007 | 3969 | 0.050 |
Why?
|
Electric Impedance | 1 | 2008 | 794 | 0.050 |
Why?
|
DNA-Binding Proteins | 1 | 2020 | 9594 | 0.050 |
Why?
|
Hemostasis, Surgical | 1 | 2004 | 127 | 0.050 |
Why?
|
International Normalized Ratio | 1 | 2005 | 381 | 0.050 |
Why?
|
Anti-Ulcer Agents | 1 | 2004 | 112 | 0.050 |
Why?
|
Ligands | 2 | 2022 | 3273 | 0.050 |
Why?
|
Cyclin D1 | 1 | 2005 | 449 | 0.050 |
Why?
|
Down-Regulation | 1 | 2010 | 2926 | 0.050 |
Why?
|
Protein Interaction Domains and Motifs | 2 | 2017 | 446 | 0.050 |
Why?
|
C-Peptide | 1 | 2004 | 443 | 0.050 |
Why?
|
Contrast Media | 1 | 2016 | 5326 | 0.050 |
Why?
|
Histamine H2 Antagonists | 1 | 2004 | 168 | 0.050 |
Why?
|
Tissue Adhesions | 1 | 2003 | 221 | 0.050 |
Why?
|
Palpation | 1 | 2002 | 166 | 0.050 |
Why?
|
Multicenter Studies as Topic | 1 | 2007 | 1731 | 0.050 |
Why?
|
Goiter | 1 | 2002 | 86 | 0.050 |
Why?
|
Thyroiditis | 1 | 2002 | 85 | 0.050 |
Why?
|
Organ Size | 1 | 2007 | 2261 | 0.050 |
Why?
|
Base Sequence | 2 | 2012 | 12402 | 0.050 |
Why?
|
Hypercalcemia | 1 | 2005 | 425 | 0.050 |
Why?
|
Preoperative Period | 2 | 2017 | 566 | 0.050 |
Why?
|
Obesity | 2 | 2016 | 13079 | 0.050 |
Why?
|
Cross-Over Studies | 2 | 2020 | 2108 | 0.050 |
Why?
|
Age Distribution | 1 | 2007 | 2859 | 0.050 |
Why?
|
Transplantation, Isogeneic | 1 | 2021 | 251 | 0.050 |
Why?
|
Career Mobility | 1 | 2023 | 259 | 0.050 |
Why?
|
Metaplasia | 1 | 2022 | 326 | 0.050 |
Why?
|
Digestive System Surgical Procedures | 1 | 2006 | 580 | 0.050 |
Why?
|
Endoscopy, Digestive System | 1 | 2004 | 358 | 0.050 |
Why?
|
HLA-A1 Antigen | 1 | 2020 | 9 | 0.050 |
Why?
|
Antigens, Viral | 1 | 2005 | 995 | 0.050 |
Why?
|
Retinoblastoma Protein | 1 | 2024 | 666 | 0.050 |
Why?
|
Transcription Factors | 1 | 2020 | 12123 | 0.040 |
Why?
|
Texas | 2 | 2012 | 410 | 0.040 |
Why?
|
Immunologic Factors | 2 | 2021 | 1585 | 0.040 |
Why?
|
Intraoperative Period | 1 | 2001 | 508 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2005 | 1059 | 0.040 |
Why?
|
Computational Biology | 1 | 2012 | 3558 | 0.040 |
Why?
|
Faculty | 1 | 2023 | 384 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8703 | 0.040 |
Why?
|
Immunoglobulin G | 1 | 2012 | 4527 | 0.040 |
Why?
|
Multiple Myeloma | 1 | 2018 | 5195 | 0.040 |
Why?
|
Postoperative Care | 1 | 2006 | 1470 | 0.040 |
Why?
|
Area Under Curve | 2 | 2016 | 1639 | 0.040 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2023 | 791 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2021 | 416 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2024 | 904 | 0.040 |
Why?
|
Workflow | 1 | 2024 | 861 | 0.040 |
Why?
|
Amiodarone | 1 | 2001 | 216 | 0.040 |
Why?
|
Liver Neoplasms | 2 | 2012 | 4352 | 0.040 |
Why?
|
Graves Disease | 1 | 2001 | 240 | 0.040 |
Why?
|
Proteasome Endopeptidase Complex | 2 | 2018 | 1314 | 0.040 |
Why?
|
Technology | 1 | 2021 | 297 | 0.040 |
Why?
|
Intestinal Diseases | 1 | 2003 | 506 | 0.040 |
Why?
|
Gastrectomy | 1 | 2004 | 694 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26284 | 0.040 |
Why?
|
Nucleotides, Cyclic | 1 | 2019 | 83 | 0.040 |
Why?
|
Prevalence | 2 | 2024 | 15833 | 0.040 |
Why?
|
Proto-Oncogene Proteins | 2 | 2015 | 4520 | 0.040 |
Why?
|
Silicon | 1 | 2019 | 141 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2015 | 5693 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2022 | 561 | 0.040 |
Why?
|
Body Mass Index | 2 | 2016 | 13044 | 0.040 |
Why?
|
Aminopyridines | 1 | 2022 | 576 | 0.040 |
Why?
|
Staining and Labeling | 1 | 2022 | 1070 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2004 | 12949 | 0.040 |
Why?
|
Patient Advocacy | 1 | 2020 | 361 | 0.040 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2023 | 1151 | 0.040 |
Why?
|
Iodine Radioisotopes | 1 | 2022 | 1027 | 0.040 |
Why?
|
Mentors | 1 | 2023 | 671 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 1 | 2022 | 2470 | 0.040 |
Why?
|
Genetic Heterogeneity | 1 | 2021 | 735 | 0.040 |
Why?
|
Mitochondrial Proteins | 1 | 2023 | 975 | 0.040 |
Why?
|
Phagocytes | 1 | 2019 | 292 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2004 | 1295 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2020 | 4850 | 0.030 |
Why?
|
Disease Models, Animal | 3 | 2022 | 18289 | 0.030 |
Why?
|
Gene Expression | 2 | 2022 | 7584 | 0.030 |
Why?
|
Mammary Glands, Human | 1 | 2018 | 199 | 0.030 |
Why?
|
Placebo Effect | 1 | 2021 | 514 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2022 | 864 | 0.030 |
Why?
|
Breast Neoplasms, Male | 1 | 2018 | 212 | 0.030 |
Why?
|
Protein Transport | 2 | 2012 | 1937 | 0.030 |
Why?
|
Antibodies, Blocking | 1 | 2017 | 249 | 0.030 |
Why?
|
Tissue Donors | 1 | 2006 | 2393 | 0.030 |
Why?
|
Genomics | 2 | 2023 | 5924 | 0.030 |
Why?
|
Glomerular Filtration Rate | 1 | 2005 | 2233 | 0.030 |
Why?
|
Transcription, Genetic | 1 | 2010 | 7599 | 0.030 |
Why?
|
Seroma | 1 | 2016 | 74 | 0.030 |
Why?
|
Central Nervous System Neoplasms | 1 | 2024 | 917 | 0.030 |
Why?
|
Cholesterol, HDL | 1 | 2022 | 1811 | 0.030 |
Why?
|
Complement Activation | 1 | 2018 | 430 | 0.030 |
Why?
|
Microspheres | 1 | 2019 | 773 | 0.030 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 2015 | 48 | 0.030 |
Why?
|
Radiotherapy, Conformal | 1 | 2019 | 533 | 0.030 |
Why?
|
Military Personnel | 1 | 2005 | 1252 | 0.030 |
Why?
|
Solubility | 1 | 2017 | 1078 | 0.030 |
Why?
|
Endometriosis | 1 | 2003 | 870 | 0.030 |
Why?
|
Epirubicin | 1 | 2015 | 82 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2229 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2024 | 1892 | 0.030 |
Why?
|
Triglycerides | 1 | 2022 | 2441 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2007 | 3478 | 0.030 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2018 | 594 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 3 | 2022 | 36537 | 0.030 |
Why?
|
Molecular Targeted Therapy | 2 | 2019 | 2822 | 0.030 |
Why?
|
Fiducial Markers | 1 | 2016 | 134 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2005 | 2794 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2021 | 1394 | 0.030 |
Why?
|
Cost of Illness | 1 | 2024 | 1949 | 0.030 |
Why?
|
Vinblastine | 1 | 2016 | 483 | 0.030 |
Why?
|
Amino Acid Motifs | 1 | 2017 | 924 | 0.030 |
Why?
|
Serine | 1 | 2018 | 824 | 0.030 |
Why?
|
BRCA2 Protein | 1 | 2019 | 801 | 0.030 |
Why?
|
RNA | 2 | 2022 | 2717 | 0.030 |
Why?
|
Surgical Wound Infection | 1 | 2004 | 1543 | 0.030 |
Why?
|
HCT116 Cells | 1 | 2015 | 399 | 0.030 |
Why?
|
Intubation, Intratracheal | 1 | 2002 | 1303 | 0.030 |
Why?
|
Immunomodulation | 1 | 2018 | 547 | 0.030 |
Why?
|
Diffusion of Innovation | 1 | 2019 | 722 | 0.030 |
Why?
|
Hematopoiesis | 1 | 2023 | 2061 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 1837 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2019 | 1183 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2024 | 3229 | 0.030 |
Why?
|
NIH 3T3 Cells | 1 | 2015 | 651 | 0.030 |
Why?
|
Stomach Neoplasms | 1 | 2004 | 1472 | 0.030 |
Why?
|
Case-Control Studies | 3 | 2017 | 22224 | 0.030 |
Why?
|
Flow Cytometry | 1 | 2024 | 5879 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2023 | 2880 | 0.030 |
Why?
|
Cholesterol, LDL | 1 | 2022 | 2393 | 0.030 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 1999 | 888 | 0.030 |
Why?
|
Fatal Outcome | 1 | 1998 | 1831 | 0.030 |
Why?
|
Genes, Insect | 1 | 1994 | 265 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2020 | 1994 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2036 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1672 | 0.030 |
Why?
|
Probability | 2 | 2008 | 2473 | 0.030 |
Why?
|
Technetium Tc 99m Sulfur Colloid | 1 | 2012 | 63 | 0.030 |
Why?
|
Thioredoxins | 1 | 1994 | 202 | 0.030 |
Why?
|
Self-Assessment | 1 | 2015 | 400 | 0.030 |
Why?
|
Diagnostic Imaging | 1 | 2006 | 3526 | 0.020 |
Why?
|
Endoplasmic Reticulum | 1 | 2018 | 1132 | 0.020 |
Why?
|
Meiosis | 1 | 1994 | 326 | 0.020 |
Why?
|
Blood Platelets | 1 | 2022 | 2463 | 0.020 |
Why?
|
Immunization | 1 | 2016 | 1218 | 0.020 |
Why?
|
Mass Screening | 1 | 2007 | 5445 | 0.020 |
Why?
|
Epitope Mapping | 1 | 2012 | 300 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2020 | 2423 | 0.020 |
Why?
|
Administration, Oral | 1 | 2019 | 4015 | 0.020 |
Why?
|
Placenta | 1 | 2020 | 1728 | 0.020 |
Why?
|
Cell Line | 1 | 2005 | 15542 | 0.020 |
Why?
|
Immunotherapy, Active | 1 | 2011 | 58 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4334 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2023 | 3617 | 0.020 |
Why?
|
Antigens, CD34 | 1 | 2012 | 656 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2012 | 868 | 0.020 |
Why?
|
Proteins | 1 | 2005 | 5996 | 0.020 |
Why?
|
ras Proteins | 1 | 2015 | 1053 | 0.020 |
Why?
|
Fluorouracil | 1 | 2015 | 1648 | 0.020 |
Why?
|
Forecasting | 1 | 2019 | 2936 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2021 | 3563 | 0.020 |
Why?
|
Remission Induction | 1 | 2015 | 2409 | 0.020 |
Why?
|
Kinetics | 1 | 2017 | 6272 | 0.020 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2020 | 1758 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2020 | 3431 | 0.020 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2010 | 304 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2022 | 4207 | 0.020 |
Why?
|
Gamma Cameras | 1 | 2008 | 35 | 0.020 |
Why?
|
Congresses as Topic | 1 | 2013 | 811 | 0.020 |
Why?
|
Immunization, Passive | 1 | 2011 | 616 | 0.020 |
Why?
|
Chronic Disease | 1 | 2003 | 9351 | 0.020 |
Why?
|
RNA Interference | 1 | 2017 | 2828 | 0.020 |
Why?
|
Genome, Human | 1 | 2021 | 4446 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3412 | 0.020 |
Why?
|
Logistic Models | 2 | 2016 | 13261 | 0.020 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2008 | 355 | 0.020 |
Why?
|
Brain Neoplasms | 2 | 2024 | 9071 | 0.020 |
Why?
|
Propensity Score | 1 | 2016 | 1968 | 0.020 |
Why?
|
Annexin A5 | 1 | 2008 | 102 | 0.020 |
Why?
|
Medication Adherence | 1 | 2019 | 2190 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2017 | 6492 | 0.020 |
Why?
|
Necrosis | 1 | 2012 | 1613 | 0.020 |
Why?
|
Ubiquitination | 1 | 2012 | 996 | 0.020 |
Why?
|
Phosphorylation | 1 | 2018 | 8279 | 0.020 |
Why?
|
Cause of Death | 1 | 1998 | 3709 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1761 | 0.020 |
Why?
|
Electrodiagnosis | 1 | 2008 | 149 | 0.020 |
Why?
|
Health Services Needs and Demand | 1 | 2015 | 1407 | 0.020 |
Why?
|
Radiography | 1 | 1998 | 6917 | 0.020 |
Why?
|
Consensus | 1 | 2016 | 3200 | 0.020 |
Why?
|
Lysosomes | 1 | 2012 | 932 | 0.020 |
Why?
|
Kidney | 1 | 2002 | 7066 | 0.020 |
Why?
|
Cytokines | 1 | 2021 | 7424 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2018 | 3683 | 0.020 |
Why?
|
Drosophila | 1 | 1994 | 1501 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2008 | 10730 | 0.020 |
Why?
|
Military Medicine | 1 | 2008 | 185 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2008 | 898 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2012 | 2720 | 0.020 |
Why?
|
Cell Movement | 1 | 2017 | 5192 | 0.020 |
Why?
|
Pregnancy | 2 | 2020 | 30248 | 0.020 |
Why?
|
Graft Survival | 1 | 2016 | 3890 | 0.020 |
Why?
|
Radionuclide Imaging | 1 | 2008 | 1978 | 0.010 |
Why?
|
Antibodies | 1 | 2012 | 2416 | 0.010 |
Why?
|
Cell Count | 1 | 2008 | 1823 | 0.010 |
Why?
|
Choice Behavior | 1 | 2010 | 846 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2011 | 1274 | 0.010 |
Why?
|
Causality | 1 | 2010 | 1246 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2012 | 4858 | 0.010 |
Why?
|
Safety | 1 | 2008 | 1157 | 0.010 |
Why?
|
Regression Analysis | 1 | 2012 | 6319 | 0.010 |
Why?
|
Graft Rejection | 1 | 2016 | 4498 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2021 | 22321 | 0.010 |
Why?
|
Research Design | 1 | 2018 | 6207 | 0.010 |
Why?
|
Immunity, Cellular | 1 | 2008 | 1554 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2007 | 3432 | 0.010 |
Why?
|
Cell Division | 1 | 2008 | 4472 | 0.010 |
Why?
|
Hematopoietic Stem Cells | 1 | 2012 | 3406 | 0.010 |
Why?
|
Health Status Disparities | 1 | 2012 | 1880 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 2012 | 4779 | 0.010 |
Why?
|
Child | 2 | 2012 | 80499 | 0.010 |
Why?
|
Health Surveys | 1 | 2007 | 4057 | 0.010 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2012 | 5753 | 0.010 |
Why?
|
Transformation, Genetic | 1 | 1994 | 194 | 0.010 |
Why?
|
Oogenesis | 1 | 1994 | 125 | 0.010 |
Why?
|
Embryonic and Fetal Development | 1 | 1994 | 419 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1994 | 1984 | 0.010 |
Why?
|
DNA Transposable Elements | 1 | 1994 | 765 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1994 | 2744 | 0.010 |
Why?
|
Homozygote | 1 | 1994 | 1774 | 0.000 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2012 | 12238 | 0.000 |
Why?
|